Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Memory & Cognition|December 8, 2025
Beyond who, what, and where: Findings from two experiments on age group differences in narrative elaborateness of autobiographical eventsDaniel E Cohen, Janice A Hayhoe, Darcey Lynn, et al.
The Journal of Infectious Diseases|May 15, 2020
Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune ActivationDonald D Anthony, Mark S Sulkowski, Laura M Smeaton, et al.
AIDS (London, England)|February 28, 2008
Increased detection of HIV-specific T cell responses by combination of central sequences with comparable immunogenicityNicole Frahm, David C Nickle, Caitlyn H Linde, et al.
Open Forum Infectious Diseases|April 21, 2021
T-cell Activation Is Correlated With Monocyte Activation in HCV/HIV Coinfection and Declines During HCV Direct-Acting Antiviral TherapyAnn W N Auma, Carey Shive, Sofi Damjanovska, et al.
Kidney International Reports|February 19, 2019
Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney DiseaseDavid E Bernstein, Albert Tran, Paul Martin, et al.
Journal of Medical Virology|March 7, 2019
Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct-acting antiviral therapyFred Poordad, Michael Bennett, Thomas E Sepe, et al.
Journal of Viral Hepatitis|January 19, 2020
Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trialsFred Poordad, RuiSarmento E Castro, Armen Asatryan, et al.
Plos Neglected Tropical Diseases|July 10, 2023
A Phase-I pharmacokinetic, safety and food-effect study on flubentylosin, a novel analog of Tylosin-A having potent anti-Wolbachia and antifilarial activityNegar Alami, David C Carter, Nisha V Kwatra, et al.
Gastroenterology|March 16, 2016
Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal DiseasePaul J Pockros, K Rajender Reddy, Parvez S Mantry, et al.
The Journal of Infectious Diseases|December 12, 2017
Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin DosageAndrew H Talal, Emily O Dumas, Barbara Bauer, et al.
Pageof 5